graph Evidence gap map comparisons
neratinib based treatmentpertuzumab based treatmenttrastuzumab based treatmenttucatinib based treatment
neratinib neratinib plus capecitabine pertuzumab plus trastuzumab pertuzumab plus trastuzumab plus docetaxel docetaxel plus carboplatin with trastuzumab followed by trastuzumab doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab trastuzumab plus endocrine therapy trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel tucatinib plus trastuzumab plus capecitabine
Comparator:  vs doxorubicin plus cyclophosphamide followed by docetaxel;   vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab;   vs placebo;   vs trastuzumab;   vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel;   vs trastuzumab plus docetaxel;   vs trastuzumab plus chemotherapy;   vs lapatinib plus capecitabine;   vs trastuzumab plus capecitabine; 
Risk of bias:  low;   some concerns;   high;  NA;